Autism Spectrum Disorder-associated Biomarkers for Case Evaluation and Management by Clinical Geneticists

David A. Geier; Mark R. Geier

Disclosures

Expert Rev Mol Diagn. 2008;8(6):671-674. 

In This Article

Conclusion

The present article provides a brief cataloging of the rapidly emerging, clinically available biomarkers that the clinician can use to evaluate ASDs, and can potentially help normalize with targeted treatments. The use of biomarkers will assist the clinical geneticist in making a differential diagnosis, and determine potential etiological factors contributing to ASDs. Finally, it is clear that, as additional research is performed, the clinical geneticist will need to give careful attention to the task of incorporating new testing and treatment options for ASDs.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....